

15 October 2022

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400051

**Symbol: BANKA****Sub: Clarification on Financial Results for 30 June 2022****Ref: Application No. 2022082097328**

Dear Sir/ Madam,

With reference to the “Clarification sought by NSE” with respect to Outcome of Board Meeting - Financial Results, submitted to the Exchange dated 10-Aug-2022, we hereby submit the following:

**1. Machine Readable Form / Legible copy of Financial Results not submitted**

We have attached herewith the Standalone and Consolidated Financial Results in Machine Readable Form.

**2. Consolidated: Segment Reporting - Not found**

In this regard, we would like to clarify that the Company operates in single segment i.e. “human waste disposal and management”, and the same has been selected while submitting the financial results. Therefore, Segment Reporting is not applicable.

**Note – please note that the delay in responding is due to over-sightedness & no other manipulative intension.**

Request to kindly consider the aforesaid clarification and do the needful in this regard.

Thank you,

**For Banka BioLoo Limited**

**T. V. Rama Krishna**  
**CFO & Executive Director**  
**DIN: 07977695**

10 August 2022

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza C-1, Block G  
Bandra Kurla Complex  
Bandra (East)  
Mumbai - 400051

**Symbol: BANKA**

**Sub: Outcome of Board Meeting held on 10 August 2022**  
**Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

With reference to the above subject, and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e., Wednesday, 10 August 2022, the Board of Directors of the Company, inter alia, discussed, considered and approved the following:

- a) Un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2022.
- b) Limited Review Report thereon as on 30 June 2022.

The meeting commenced at 3.30 PM and concluded at 6.45 PM.

This is for your information and records.

Thank you!

**For Banka BioLoo Limited**



**Sri Bala Aditya Yanamandra**  
**Company Secretary & Compliance Office**

10 August 2022

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza C-1, Block G  
Bandra Kurla Complex  
Bandra (East)  
Mumbai - 400051

**Symbol: BANKA**

**Sub: Submission of un-audited financial results (both standalone and Consolidated) for the quarter ended 30 June 2022 along with Limited Review Report thereon**

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable circulars, we herewith enclose the following:

- Un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2022;
- Limited Review Report thereon as on 30 June 2022.

The aforesaid financial results are duly approved and recommended by the Audit Committee in their meeting held on 10 August 2022.

These are also being made available on the website of the Company at [www.bankabio.com](http://www.bankabio.com).

Kindly take the same on record.

Thank you,

**For Banka BioLoo Limited**

**Sri Bala Aditya Yanamandra**  
**Company Secretary and Compliance Officer**

*Encls. as above*



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of BANKA BIOLOO LIMITED**

We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter ended June 30, 2022 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2020 ('the Circular').

1. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review
2. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed

**For PRSV & Co. LLP**

Chartered Accountants

Firm Registration No: S200016

  
Y. Venkateswarlu

Partner

Membership No: 222068

Place: Hyderabad

Date: 10-08-2022



**UDIN: 22222068AOTRQR5831**

**BANKA BIOLOO LIMITED**

Unaudited STANDALONE Statement of Financial Results for the quarter ended 30 June 2022

S. No	Particulars	Quarter ended			Year ended
		Unaudited	Audited	Unaudited	Audited
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
1	<b>Income</b>				
	Revenue from Operations	939.35	1023.67	803.00	3863.38
	Other income	8.11	10.18	12.05	45.37
	<b>Total Income</b>	<b>947.46</b>	<b>1033.85</b>	<b>815.05</b>	<b>3908.75</b>
2	<b>Expenses</b>				
	Cost of materials consumed	174.80	106.02	147.53	774.66
	Changes in inventories of finished goods & work-in-progress	(58.33)	(13.64)	(7.08)	(107.80)
	Employee benefits expense	541.07	500.43	349.22	1774.16
	Finance costs	41.33	45.62	41.14	173.13
	Depreciation and amortisation expense	31.12	27.73	19.80	94.06
	Other expenses	176.89	258.48	207.86	874.54
	<b>Total expenses</b>	<b>906.87</b>	<b>924.64</b>	<b>758.46</b>	<b>3582.75</b>
3	<b>Profit/(loss) before tax</b>	<b>40.60</b>	<b>109.20</b>	<b>56.59</b>	<b>326.00</b>
4	<b>Tax expense</b>				
	(1) Current tax	3.55	8.74	0.00	27.88
	(2) Taxes for earlier years	0.00	0.00	0.00	0.00
	(3) MAT Credit	0.00	0.00	0.00	0.00
	(4) Deferred tax	(10.20)	1.85	(8.61)	(7.75)
	<b>Total Tax expense</b>	<b>(6.64)</b>	<b>10.59</b>	<b>(8.61)</b>	<b>20.13</b>
5	<b>Profit after tax</b>	<b>47.24</b>	<b>98.61</b>	<b>65.20</b>	<b>305.87</b>
	<b>Other comprehensive income</b>				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations	-	4.51	-	4.51
	Income tax effect on items that will not be reclassified to	-	(1.10)	-	(1.10)
	<b>Other comprehensive income for the year</b>	<b>-</b>	<b>3.40</b>	<b>-</b>	<b>3.40</b>
	<b>Total comprehensive income for the year</b>	<b>47.24</b>	<b>102.02</b>	<b>65.20</b>	<b>309.27</b>
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1028.11	1084.66
7	<b>Earnings per share</b>				
	Basic and Diluted Earnings per share (in Rs.)	0.44	0.96	0.63	2.97
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For PRSV & Co. LLP  
Chartered Accountants  
FRN No. S200016

Y. Venkateswarlu  
Partner  
M.No.222068



FOR & ON BEHALF OF BOARD OF DIRECTORS

Namita Banka  
Managing Director  
DIN: 05017358



Place: Hyderabad  
Date: 10.08.2022

**Notes:**

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 10 August 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter ended 30 June 2022 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31<sup>st</sup> March 2022.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. During the financial year ended 31<sup>st</sup> March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
7. The results for the quarter ended March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and published year to date figures up to third quarter of the respective financial year then ended.
8. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 30.06.2022	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.14	
	<b>Total</b>	<b>1,262.70</b>	<b>1191.92</b>	-

9. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
10. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.



Place: Hyderabad  
Date: 10 August 2022

For Banka BioLoo Limited

*Namita Banka*

Namita Banka  
Managing Director  
DIN: 05017358





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
Board of Directors of **BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BANKA BIOLOO LIMITED** (The Parent") and its subsidiary (The parent and its subsidiaries and its associate together referred to as the "Group") for the quarter ended 30 June 2022 ("the statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended to the extent applicable.

4. The Statement includes the results of the following entities.

**Holding/Parent Company**

**BANKA BIOLOO LIMITED**

**Wholly Owned Subsidiary**

**ENZOTECH SOLUTIONS PRIVATE LIMITED**

**Associate**

**SAI BANKA SPV PRIVATE LIMITED**

**SUSTAINABLE SANITATION INDUSTRY ASSOCIATION**




Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

**Other Matter**

We did not review the interim financial information of four subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 173.14 Lacs (After excluding intercompany revenue of Rs. 51.98 Lacs), total net profit after tax of Rs.6.21 Lacs and total comprehensive income of Rs. 6.21 Lacs for the quarter ended June 30, 2022, as considered in the statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of other auditors and the procedures performed by us as stated above. The statement also includes financial results of 2 associates as mentioned above, whose share of net profit after tax of Rs. 2.46 Lacs and total comprehensive income of Rs. 2.46 Lacs for the quarter ended June 30, 2022, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed and which has been furnished to us by the Management.

**For PRSV & Co LLP**  
Chartered Accountants  
Firm Registration No. S200016

  
**Y. Venkateswarlu**  
Partner  
M. No. 222068



Place: Hyderabad  
Date: 10-08-2022

**UDIN: 2222068AOTSEW2568**



**BANKA BIOLOO LIMITED**

Unaudited CONSOLIDATED Statement of Financial Results for the quarter ended 30 June 2022

S. No	Particulars	Quarter ended			Year ended
		30.06.2022 Unaudited	31.03.2022 Audited	30.06.2021 Unaudited	31.03.2022 Audited
1	<b>Income</b>				
	Revenue from Operations	1,110.23	1035.37	803.00	3875.08
	Other income	10.37	10.18	12.05	45.37
	<b>Total Income</b>	<b>1,120.61</b>	<b>1045.55</b>	<b>815.05</b>	<b>3920.45</b>
2	<b>Expenses</b>				
	Cost of materials consumed	273.37	110.03	147.53	778.67
	Changes in inventories of finished goods & work-in-progress	(68.57)	(12.38)	(7.08)	(106.54)
	Employee benefits expense	575.77	502.69	349.22	1776.42
	Finance costs	46.47	46.28	41.14	173.78
	Depreciation and amortisation expense	32.33	27.81	19.80	94.15
	Other expenses	214.44	259.73	207.86	875.79
	<b>Total expenses</b>	<b>1,073.81</b>	<b>934.16</b>	<b>758.46</b>	<b>3592.27</b>
3	Share of profit/(loss) of Associates	2.46	4.46	(0.61)	2.71
4	<b>Profit/(loss) before tax</b>	<b>49.26</b>	<b>115.85</b>	<b>55.97</b>	<b>330.89</b>
5	<b>Tax expense</b>				
	(1) Current tax	3.55	8.74	-	27.88
	(2) Taxes for earlier years	-	0.00	-	0.00
	(3) MAT Credit	-	0.00	-	0.00
	(4) Deferred tax	(10.20)	1.85	(8.61)	(7.75)
	<b>Total Tax expense</b>	<b>(6.65)</b>	<b>10.59</b>	<b>(8.61)</b>	<b>20.13</b>
6	<b>Profit after tax</b>	<b>55.91</b>	<b>105.26</b>	<b>64.59</b>	<b>310.76</b>
	<b>Other comprehensive income</b>				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations		4.51	-	4.51
	Income tax effect on items that will not be reclassified		(1.10)	-	(1.10)
	<b>Other comprehensive income for the year</b>	<b>-</b>	<b>3.40</b>	<b>-</b>	<b>3.40</b>
	<b>Total comprehensive income for the year</b>	<b>55.91</b>	<b>108.66</b>	<b>64.59</b>	<b>314.17</b>
	<b>Attributable to</b>				
	Shareholders of the Company	55.91	108.66	64.59	314.17
	Non controlling interest	-	0.00	0.00	0.00
7	Paid up equity share capital (Face value Rs. 10/- each)	1,084.66	1084.66	1,028.11	1084.66
8	Earnings per share				
	Basic and Diluted Earnings per share (in Rs.)	0.52	1.02	0.63	3.02
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)


FOR & ON BEHALF OF BOARD OF DIRECTORS

For PRSV & Co. LLP  
Chartered Accountants  
FRN No. S-200016

Y. Venkateswarlu  
Partner  
M.No.222068



*Namita Banka*  
Namita Banka  
Managing Director  
DIN: 05017358



Place: Hyderabad  
Date: 10.08.2022

**Notes:**

1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 10 August 2022.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.


Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
6. The results for the quarter ended March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and published year to date figures up to third quarter of the respective financial year then ended.
7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka BioLoo Limited**

*Namita Banka*

**Namita Banka**  
Managing Director  
DIN: 05017358



Place: Hyderabad  
Date: 10 August 2022



10 August 2022

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza C-1, Block G  
Bandra Kurla Complex  
Bandra (East)  
Mumbai - 400051

**Symbol: BANKA**

**Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 30 June 2022**

Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 30 June 2022.

This is for your information and necessary records.

Thank you!

**For Banka BioLoo Limited**

**Sri Bala Aditya Yanamandra**  
**Company Secretary and Compliance Officer**

## **Statement of Deviation(s) or Variation(s) Under Regulation 32(1) of Sebi (LODR) Regulations, 2015**

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter ended 30 June 2022.

**a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;**

We inform you that there was no deviation in the utilization of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

**b) Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it, in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilization of funds**

We inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for initial public offering of securities, as per regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you!

**For Banka BioLoo Limited**

*Namita Sanjay Banka*



**Namita Sanjay Banka**  
**Managing Director**  
**DIN: 05017358**